Copyright © 2004 Elsevier Inc. All rights reserved.
Associate editor: N.W. Quick
Anandamide transport
Available online 30 September 2004.
Abstract
N-Arachidonylethanolamine (anandamide) is an endogenous agonist of the cannabinoid CB1 and CB2 receptors and displays many of the same receptor-mediated physiological effects as Δ9-tetrahydrocannabinol (Δ9-THC), the active component of marijuana. As with any neurotransmitter, there must be tight control of anandamide receptor-mediated signaling and a means of rapid removal of the molecule from the system. Thus, the process by which anandamide is transported into the cell for metabolism has been a topic of much interest and has been implicated as a potential drug target in the treatment of several disease states that are reported to have an association with the endocannabinoid system. In this review, we will discuss the current models proposed for the mechanism of anandamide transport, the progress that has been made in the development of compounds that specifically inhibit anandamide transport, the observed effects of anandamide transport inhibition in vivo, and finally, potential therapeutic applications of compounds that inhibit anandamide transport.
Keywords: Cannabinoid; Anandamide; Transporter; Δ9-Tetrahydorcannabinol; Marijuana; Amidohydrolyase
Abbreviations: Δ9-THC, Δ9-tetrahydrocannabinol; 2-AG, sn2-arachidonyl glycerol; AEA, anandamide; CREAE, chronic relapsing experimental allergic encephalomyelitis; CNS, central nervous system; DAG, diacylglycerol; FAAH, fatty acid amide hydrolase; FAAH−/− mice, FAAH knockout mice; MAFP, methylarachidonylfluorophosphonate; GI, gastrointestinal; NAPE, N-arachidonylphosphatidylethanolamine; PLD, phospholipase D; PMSF, phenylmethylsulfonyl fluoride; SARI, selective AEA reuptake inhibitors; TRPV1, transient receptor potential vanilloid type 1 receptor; virodhamine, O-arachidonoyl-ethanolamine
Article Outline
- 1. Introduction
- 1.1. Cannabinoid receptors
- 1.2. Anandamide as an endogenous cannabinoid
- 1.3. Biosynthesis of anandamide
- 1.4. Termination of anandamide signaling
- 2. Anandamide transport
- 2.1. Anandamide transport by a carrier-mediated process
- 2.2. Facilitated diffusion mediated by fatty acid amide hydrolase
- 2.3. Sequestration of anandamide by cells
- 2.4. Anandamide uptake by endocytic processes
- 2.5. Inhibition of anandamide transport
- 3. In vivo studies of anandamide transport and metabolism
- 4. Potential therapeutic implications of anandamide transport inhibition
- 4.1. Analgesia
- 4.2. Anxiety
- 4.3. Spasticity
- 4.4. Neuropsychiatric disorders
- 4.5. Other potential therapeutic applications
- 5. Discussion
- Acknowledgements
- References






E-mail Article
Add to my Quick Links

Cited By in Scopus (53)







